Zim Laboratories Ltd received Marketing Authorization for Dimethyl Fumarate 120 mg & 240 mg Modified Release Capsules from INFARMED in Portugal on March 19, 2025, enabling expansion into EU and UK markets with a potential market size of around USD 800 million.